Podcast

ASCRS 2020: Corneal CXL outcomes in children with progressive keratoconus

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Soroosh Behshad, MD, MPH, of the Emory Eye Center, speaks with Ophthalmology Times'® David Hutton on the key takeaways from the presentation on, "Corneal crosslinking outcomes in children with progrssive keratoconus," during the 2020 ASCRS virtual meeting.

See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
Related Content
European Commission approves low-dose atropine eye drop Ryjunea from Santen
June 7th 2025

European Commission approves low-dose atropine eye drop Ryjunea from Santen

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Swept-source AS-OCT aids in early diagnosis of childhood glaucoma
May 29th 2025

Swept-source AS-OCT aids in early diagnosis of childhood glaucoma

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies
May 27th 2025

Ocugen’s OCU410ST receives rare pediatric disease designation for the treatment of ABCA4-associated retinopathies

© 2025 MJH Life Sciences

All rights reserved.